| Title |
Pathophysiological and Pharmacological Rationale for the Use of Exenatide Once Weekly in Patients with Type 2 Diabetes
|
|---|---|
| Published in |
Advances in Therapy, February 2014
|
| DOI | 10.1007/s12325-014-0101-4 |
| Pubmed ID | |
| Authors |
Samuel S. Grossman |
| Abstract |
A new formulation of exenatide has become available recently that is the first antidiabetic medication for type 2 diabetes mellitus (T2DM) dosed on a weekly schedule. This review summarizes the pharmacology, efficacy, and safety of exenatide once weekly (exenatide QW). The results are interpreted in terms of the pathophysiology of T2DM, as well as the pharmacology of the new formulation. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 1 | 50% |
| Unknown | 1 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 50% |
| Science communicators (journalists, bloggers, editors) | 1 | 50% |
Mendeley readers
The data shown below were compiled from readership statistics for 49 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 49 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 10 | 20% |
| Researcher | 9 | 18% |
| Student > Ph. D. Student | 6 | 12% |
| Other | 5 | 10% |
| Student > Bachelor | 4 | 8% |
| Other | 4 | 8% |
| Unknown | 11 | 22% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 15 | 31% |
| Pharmacology, Toxicology and Pharmaceutical Science | 9 | 18% |
| Agricultural and Biological Sciences | 4 | 8% |
| Environmental Science | 2 | 4% |
| Computer Science | 1 | 2% |
| Other | 6 | 12% |
| Unknown | 12 | 24% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 06 June 2014.
All research outputs
#17,713,929
of 22,745,803 outputs
Outputs from Advances in Therapy
#1,493
of 2,336 outputs
Outputs of similar age
#156,510
of 223,888 outputs
Outputs of similar age from Advances in Therapy
#15
of 21 outputs
Altmetric has tracked 22,745,803 research outputs across all sources so far. This one is in the 19th percentile – i.e., 19% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,336 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.3. This one is in the 30th percentile – i.e., 30% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 223,888 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 26th percentile – i.e., 26% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 21 others from the same source and published within six weeks on either side of this one. This one is in the 28th percentile – i.e., 28% of its contemporaries scored the same or lower than it.